UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

Journal of clinical oncology, 2016-11, Vol.34 (31), p.3803-3815

LoRusso, Patricia Mucci

2016

Volltextzugriff (PDF)

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The lancet oncology, 2017-06, Vol.18 (6), p.743-754

2017

Volltextzugriff (PDF)

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

JNCI : Journal of the National Cancer Institute, 2023-02, Vol.115 (2), p.122-124

2023

Volltextzugriff (PDF)

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.689-699

2014

Volltextzugriff (PDF)

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Clinical cancer research, 2011-10, Vol.17 (20), p.6437-6447

2011

Volltextzugriff (PDF)

Phase I trials as valid therapeutic options for patients with cancer

Nature reviews. Clinical oncology, 2019-12, Vol.16 (12), p.773-778

2019

Volltextzugriff (PDF)

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

Pigment cell and melanoma research, 2020-05, Vol.33 (3), p.390-402

2020

Volltextzugriff (PDF)

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

Clinical cancer research, 2009-04, Vol.15 (7), p.2207-2214

2009

Volltextzugriff (PDF)

One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable

The New England journal of medicine, 2020-09, Vol.383 (13), p.1277-1278

2020

Volltextzugriff (PDF)

Evaluation of pre-analytical factors affecting plasma DNA analysis

Scientific reports, 2018-05, Vol.8 (1), p.7375-10, Article 7375

2018

Volltextzugriff (PDF)

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

Clinical cancer research, 2015-01, Vol.21 (1), p.60-67

2015

Volltextzugriff (PDF)

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

JAMA oncology, 2016-01, Vol.2 (1), p.46

2016

Volltextzugriff (PDF)

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Volltextzugriff (PDF)

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Clinical cancer research, 2018-08, Vol.24 (16), p.3820-3828

2018

Volltextzugriff (PDF)

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Current drug metabolism, 2012-09, Vol.13 (7), p.901-910

2012

Volltextzugriff (PDF)

Next-Generation Sequencing to Guide Clinical Trials

Clinical cancer research, 2015-10, Vol.21 (20), p.4536-4544

2015

Volltextzugriff (PDF)

Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer

Mayo Clinic proceedings, 2017-10, Vol.92 (10), p.1583-1591

2017

Volltextzugriff (PDF)

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors

The oncologist (Dayton, Ohio), 2013-07, Vol.18 (7), p.819-820

2013

Volltextzugriff (PDF)

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Clinical cancer research, 2012-01, Vol.18 (2), p.568-576

2012

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

Clinical cancer research, 2011-04, Vol.17 (8), p.2502-2511

2011

Volltextzugriff (PDF)

Review: Targeting the Hedgehog pathway in cancer

Therapeutic Advances in Medical Oncology, 2010-07, Vol.2 (4), p.237-250

2010

Volltextzugriff (PDF)

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

The New England journal of medicine, 2009-09, Vol.361 (12), p.1173-1178

2009

Volltextzugriff (PDF)

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Volltextzugriff (PDF)

1 – 25 von 676

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(654)
Mit Volltextzugriff
(616)

Publikationsform

Sprache

Englisch
(676)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(338)
Life Sciences & Biomedicine
(327)
Humans
(300)
Oncology
(285)
Female
(217)
Middle Aged
(177)
Male
(174)
Aged
(165)
Adult
(154)
Neoplasms - Drug Therapy
(140)
Tumors
(131)
Biological And Medical Sciences
(118)
Medical Sciences
(118)
Pharmacology & Pharmacy
(102)
Pharmacology. Drug Treatments
(100)
Antineoplastic Agents
(94)
Aged, 80 And Over
(76)
Dose-Response Relationship, Drug
(73)
Antineoplastic Agents - Therapeutic Use
(71)
Pharmacokinetics
(71)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Phase I trials as valid therapeutic options for patients with cancer

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable

Evaluation of pre-analytical factors affecting plasma DNA analysis

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Next-Generation Sequencing to Guide Clinical Trials

Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer

Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

Review: Targeting the Hedgehog pathway in cancer

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Suchergebnisse filtern